MAGGI, CLAUDIA
MAGGI, CLAUDIA
Universita' degli Studi di MILANO
Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer : a Retrospective Comparison of Efficacy and Safety Profiles
2019 C. Vernieri, M. Prisciandaro, M. Milano, M.S. Cona, C. Maggi, M. Brambilla, A. Mennitto, C. Fabbroni, E. Farè, S. Cresta, L. Celio, G. Mariani, G. Bianchi, G. Capri, F. de Braud
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives
2019 C. Vernieri, M. Milano, M. Brambilla, A. Mennitto, C. Maggi, M.S. Cona, M. Prisciandaro, C. Fabbroni, L. Celio, G. Mariani, G.V. Bianchi, G. Capri, F. de Braud
GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab : A clinical and translational study
2016 F. Pietrantonio, R. Berenato, C. Maggi, M. Caporale, M. Milione, F. Perrone, E. Tamborini, D. Baratti, S. Kusamura, L. Mariani, M. Niger, A. Mennitto, A. Gloghini, I. Bossi, G. Settanni, A. Busico, P.F. Bagnoli, M. Di Bartolomeo, M. Deraco, F. de Braud
Treatment of elderly patients with metastatic renal cell carcinoma
2016 E. Zanardi, P. Grassi, A. Cavo, E. Verzoni, C. Maggi, F. De Braud, F. Boccardo, G. Procopio
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer
2016 F. Pietrantonio, F. de Braud, M. Milione, C. Maggi, R. Iacovelli, K.F. Dotti, F. Perrone, E. Tamborini, M. Caporale, R. Berenato, G. Leone, A. Pellegrinelli, I. Bossi, F. Festinese, S. Federici, M. Di Bartolomeo
Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer : A systematic review and meta-analysis of published trials
2016 R. Iacovelli, F. Pietrantonio, C. Maggi, F. de Braud, M. Di Bartolomeo
DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan
2015 F.S. Falvella, S. Cheli, A. Martinetti, C. Mazzali, R. Iacovelli, C. Maggi, M. Gariboldi, M.A. Pierotti, M. Di Bartolomeo, E. Sottotetti, R. Mennitto, I. Bossi, F. de Braud, E. Clementi, F. Pietrantonio
Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer : an Italian Trials of Medical Oncology phase II study
2015 M. Di Bartolomeo, A. Ciarlo, A. Bertolini, S. Barni, C. Verusio, E. Aitini, F. Pietrantonio, R. Iacovelli, K.F. Dotti, C. Maggi, F. Perrone, E. Bajetta
Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab
2015 V. Musella, F. Pietrantonio, E. Di Buduo, R. Iacovelli, A. Martinetti, E. Sottotetti, I. Bossi, C. Maggi, M. Di Bartolomeo, F. de Braud, M.G. Daidone, V. Cappelletti
Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases
2015 F. Pietrantonio, V. Mazzaferro, R. Miceli, C. Cotsoglou, F. Melotti, G. Fanetti, F. Perrone, P. Biondani, C. Muscarà, M. Di Bartolomeo, J. Coppa, C. Maggi, M. Milione, E. Tamborini, F. de Braud
Bevacizumab treatment in the elderly patient with metastatic colorectal cancer
2015 M. Di Bartolomeo, C. Maggi, F. Ricchini, F. Pietrantonio, R. Iacovelli, F. de Braud, A. Inno
In reply
2015 D. Baratti, S. Kusamura, C. Maggi, F. Debraud, M. Deraco, M. Dibartolomeo, F. Pietrantonio
Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase
2015 F.S. Falvella, M. Caporale, S. Cheli, A. Martinetti, R. Berenato, C. Maggi, M. Niger, F. Ricchini, I. Bossi, M. Di Bartolomeo, E. Sottotetti, F.F. Bernardi, F. de Braud, E. Clementi, F. Pietrantonio
First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer : a systematic review and meta-analysis
2015 F. Pietrantonio, C. Cremolini, F. Petrelli, M. Di Bartolomeo, F. Loupakis, C. Maggi, C. Antoniotti, F. de Braud, A. Falcone, R. Iacovelli
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab : a meta-analysis
2015 F. Pietrantonio, F. Petrelli, A. Coinu, M. Di Bartolomeo, K. Borgonovo, C. Maggi, M. Cabiddu, R. Iacovelli, I. Bossi, V. Lonati, M. Ghilardi, F. De Braud, S. Barni
TP53 mutations in advanced colorectal cancer : the dark side of the moon
2014 F. Pietrantonio, P. Biondani, F. Perrone, M. Di Bartolomeo, M. Pacifici, M. Milione, F. Melotti, C. Maggi, G. Montemurro, I. Bossi, L. Mariani, F. De Braud
Role of MGMT as biomarker in colorectal cancer
2014 A. Inno, G. Fanetti, M. Di Bartolomeo, S. Gori, C. Maggi, M. Cirillo, R. Iacovelli, F. Nichetti, A. Martinetti, F. de Braud, I. Bossi, F. Pietrantonio
Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil : a meta-analysis of published trials
2014 R. Iacovelli, F. Pietrantonio, A. Palazzo, C. Maggi, F. Ricchini, F. De Braud, M. Di Bartolomeo
FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma
2014 F. Pietrantonio, C. Maggi, G. Fanetti, R. Iacovelli, M. Di Bartolomeo, F. Ricchini, M. Deraco, F. Perrone, D. Baratti, S. Kusamura, E. Tamborini, A. Castano, P.V. Consonni, I. Bossi, C. Gavazzi, M. Milione, G. Pelosi, F. de Braud
Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies
2014 R. Iacovelli, F. Pietrantonio, A. Farcomeni, C. Maggi, A. Palazzo, F. Ricchini, F. De Braud, M. Di Bartolomeo